GenScript ProBio
Offering Comprehensive Solutions to Facilitate Drug Discovery

The history of drug discovery and medicine is as ancient as humanity. Modern drug discovery started to emerge by the end of the 20th century and today the global drug discovery services market is thriving on account of the rising impetus given to research and development across various industries. Drug discovery is a significant component of the pharmaceutical industry, and researchers’ extensive efforts to develop new drug models have revolutionized the market. Pharmaceutical companies are increasingly concerned about producing unique treatments and eliminating any obstacles from the drug discovery process. As a result, outsourcing drug discovery has become a popular trend among these organisations, driving up demand in the market. To this end, GenScript, the world’s leading biotech company provides life sciences services and products. With gene synthesis, peptide, protein, antibody and preclinical drug development service capabilities, the firm is internationally recognized as a leading biotech company specializing in fundamental life sciences research and early-phase drug discovery services.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services. GenScript currently has more than 3000 employees globally, 33% of whom hold Masters and Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 100 patents and over 270 patent applications. As of January 2019, GenScript’s products and services have been cited by 36,500 scientific papers worldwide. GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

GenScript biotech corporation, the ‘company’ or ‘GenScript’, together with its subsidiaries, the ‘group’ is a well-recognised biotechnology company.

Based on its proprietary gene synthesis technology and the other technology and know-hows on life-science research and application, the firm has four well established major platforms including: a leading life-science services and products platform to provide one-stop solutions to global research communities, a biologics contract development and manufacturing organization ‘CDMO’ platform, an industrial synthetic products platform, and an integrated global cell therapy platform. The above four internally built platforms have demonstrated their strong growth from research and development to commercial delivery for year ended December 31, 2020 respectively.

GenScript ProBio is the subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine, biologics discovery and antibody protein drug to accelerate drug development for customers.

GenScript ProBio’s total cell and gene therapy solution covers CMC of plasmid and virus for IND filing as well as clinical manufacturing and commercial manufacturing. In plasmid service, it has established the largest commercial GMP plasmid manufacturing facility and also is the first GMP manufacturing platform to provide in vitro transcription (IVT) template linearized plasmids for mRNA vaccines. As the first lentiviral vector CDMO and the leading adeno-associated viral (AAV) supplier in China, it has established two core technology platforms: lentiviral vector and AAV vector. Both LVV and AAV suspension platform own self-developed lentiviral vector suspension cell line.

Driven by the corporate mission of making people and nature healthier through biotechnology, we at GenScript Biotech strive to become the most trustworthy biotech company in the world

GenScript ProBio’s innovative solutions for biologics discovery and development include therapeutic antibody discovery, antibody engineering and antibody characterization. In biologics development service, it has built a DNA to GMP material platform, including stable cell line development, host cell license, process development, analytical development to clinical manufacturing, and offer fed-batch and perfusion process to meet the growing needs for antibody and protein drugs.

For the road ahead, GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology. Toward the mission of ‘Innovation through Collaboration’, GenScript ProBio is also committed to helping customer’s significantly lower R&D costs and building a healthier future.